EU/3/19/2198

About

On 21 August 2019, orphan designation EU/3/19/2198 was granted by the European Commission to Ziopharm Oncology Limited, Ireland, for adenoviral vector serotype 5 encoding the human interleukin-12 p70 transgene under the control of activator ligand veledimex (also known as Ad-RTS-hIL-12) for the treatment of glioma.

Key facts

Active substance
Adenoviral vector serotype 5 encoding the human interleukin-12 p70 transgene under the control of activator ligand veledimex
Disease / condition
Treatment of glioma
Date of first decision
21/08/2019
Outcome
Positive
EU designation number
EU/3/19/2198

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Ziopharm Oncology Limited
1 Castlewood Avenue
Rathmines
Dublin 6 D06 H685
Co. Dublin
Ireland
Tel: +353 1 4970935
E-mail: infoeu@ziopharm.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

How useful was this page?

Add your rating